Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Calidi Biotherapeutics Inc (CLDI)

24 + Investors. Track Smart Money conviction in CLDI. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -5
Streak
1Q ▼
Buyers last Q
55%

Smart Money Signals — CLDI

Based on 24 hedge funds · latest filing: 2026 Q2 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their CLDI positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
🔻

Below peak — only 65% of 2.2Y high

65% of all-time peak
Only 24 funds hold CLDI today versus a peak of 37 funds at 2025 Q1 — just 65% of the maximum. Low institutional ownership can mean the stock is out of favor, but it also means there's a large pool of potential buyers if sentiment turns.
📉

Outflows — 31% fewer funds vs a year ago

fund count last 6Q
11 fewer hedge funds hold CLDI compared to a year ago (-31% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.
🟡

Slight buying edge — 55% buying

12 buying10 selling
Last quarter: 12 funds bought or added vs 10 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
➡️

Steady new buyers — ~5 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 5 → 7 → 8 → 5. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔄

Mostly new holders — 33% entered in last year

■ 4% conviction (2yr+) ■ 62% medium ■ 33% new
Only 1 funds (4%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
➡️

Steady discovery — ~5 new funds/quarter

5 → 5 → 7 → 8 → 5 new funds/Q
New funds entering each quarter: 5 → 7 → 8 → 5. Consistent flow of new institutional buyers without clear acceleration or slowdown.
📊

Mixed cohorts — 0% veterans, 38% new entrants

■ 0% veterans ■ 62% 1-2yr ■ 38% new
Of 24 current holders: 0 (0%) held 2+ years, 15 held 1–2 years, 9 (38%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.
✅

Strong quality — 30% AUM from major funds

30% from top-100 AUM funds
5 of 24 holders rank in the top 100 by AUM, accounting for 30% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
2.1
out of 10
Low Exit Risk
Exit risk score 2.1/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CLDI

In 2026 Q2, 12 hedge funds were net buyers of CLDI (5 opened a new position, 7 added to an existing one), while 10 reduced or exited (10 sold completely) — a 55% buyer ratio, indicating a slight buying edge. 30% of total institutional value in CLDI is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: -5 funds (more exits than new entries). Total institutional holders: 24.

Hedge Fund Ownership: CLDI

How many hedge funds hold CLDI — quarterly history vs. share price
Quarterly hedge fund ownership of CLDI vs. share price

Market Analysis: CLDI

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CLDI

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Calidi Biotherapeutics Inc (CLDI) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much CLDI has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 60d ago
CLDI
-52.2%
XLV
+8.1%

CLDI outperformed XLV by -60.3% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 15d ago
CLDI
-18.2%
XLV
+2.5%

Since the filing became public, CLDI outperformed XLV by -20.7% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

2 top-rated funds 0 high-conviction
Consensus
2.1
/ 10
breadth
×
Elite
0.0
/ 10
conviction
Hedge Fund Positioning: CLDI
24 + Investors

Track Smart Money conviction in CLDI. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 24 29 -17.24%
13F Shares 526K 2M -73.84%
Total Value $89K $709K -87.39%
New Positions 5 8 -3
Increased Positions 7 7 -
Closed Positions 10 5 +5
Reduced Positions 0 3 -3
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: CLDI

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

24 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CLDI. Verified SEC 13F-HR filings.

QUARTER:
Top 21 CLDI holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Rs Crum INC. 0.00% 43,239 $7K
2 Independent Advisor Alliance 0.00% 45,000 $8K
3 Belpointe Asset Management LLC 0.00% 19,921 $3K
4 Arax Advisory Partners 0.00% 37,345 $6K
5 RFG Advisory, LLC 0.00% 12,000 $2K
6 Private Advisor Group, LLC 0.00% 30,000 $5K
7 HighTower Advisors, LLC 0.00% 83,523 $14K
8 Farther Finance Advisors, LLC 0.00% 10,000 $2K
9 Reyes Financial Architecture, Inc. 0.00% 100 —
10 Finepoint Capital LP 0.00% 1,042 —
11 Tower Research Capital LLC (TRC) 0.00% 1,396 —
12 Highbridge Capital Management LLC 0.00% 1,042 —
13 Tradewinds Capital Management, LLC 0.00% 101 —
14 SBI Securities Co., Ltd. 0.00% 375 —
15 Jane Street Group, LLC 0.00% 54,274 $9K
16 Osaic Holdings, INC. 0.00% 2,650 —
17 Citigroup Inc 0.00% 4,594 —
18 UBS Group AG 0.00% 7,882 $1K
19 Morgan Stanley 0.00% 13,244 $2K
20 Vanguard Capital Management LLC 0.00% 25,509 $4K
21 Mercer Global Advisors Inc /Adv 0.00% 50 —
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Calidi Biotherapeutics Inc (CLDI)

What does the Smart Money Trend signal show for CLDI?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their CLDI positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for CLDI?

Slight buying edge — 55% buying: Last quarter: 12 funds bought or added vs 10 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for CLDI holders?

Strong quality — 30% AUM from major funds: 5 of 24 holders rank in the top 100 by AUM, accounting for 30% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held CLDI?

Mostly new holders — 33% entered in last year: Only 1 funds (4%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Calidi Biotherapeutics Inc (CLDI) following the 2026 Q2 hedge fund 13F filings?

As of today, CLDI has moved -18.2% since the 2026 Q2 13F filing date (August 14, 2026), compared to +2.5% for the XLV sector ETF — an outperformance of -20.7%. Since the quarter end (June 30, 2026), CLDI has gained -52.2% vs +8.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →